World Journal of Pediatrics

, 5:265 | Cite as

Vitiligo in children

  • Talia KakourouEmail author
Review Article



Vitiligo is an acquired depigmentary disorder affecting around 1% of the world’s population. In 25% of cases it has its onset prior to the age of 14 years.

Data sources

Articles on vitiligo in children published after 1995 were retrieved from PubMed. The prevalence, etiology, clinical presentation, differential diagnosis, treatment and management of vitiligo in children were summarized.


Vitiligo is characterized by acquired, sharply demarcated depigmented macules or patches on the skin, the mucous membranes and/or white hair and it is mainly differentiated from congenital achromic skin lesions. It is frequently associated with various autoimmune diseases. Hashimoto’s thyroiditis is the most common association in children. Information on the nature, possible causes and course of the disease leads to acceptance of the disorder and higher compliance with the treatment. The choice of medical treatment depends on the type, location and duration of lesions as well as the eagerness of the child and his/her parents to pursue therapy.


The management of childhood vitiligo includes information and reassurance of young patients and their parents on the disease, thyroid investigation, avoidance of trigger factors, topical treatment and proper follow-up.

Key words

management thyroiditis treatment vitiligo 


  1. 1.
    Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647–666.CrossRefPubMedGoogle Scholar
  2. 2.
    Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from North India. Pediatr Dermatol 2003;20:207–210.CrossRefPubMedGoogle Scholar
  3. 3.
    Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167–181.CrossRefPubMedGoogle Scholar
  4. 4.
    Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun 2005;25Suppl:63–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Dell’anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006;19:406–411.CrossRefPubMedGoogle Scholar
  6. 6.
    Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, Kaloumenou E, Chrousos GP. Increased prevalence of chronic autoimmune (Hashimoto’s) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005;53:220–223.CrossRefPubMedGoogle Scholar
  7. 7.
    Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol 1996;35:620–626.CrossRefPubMedGoogle Scholar
  8. 8.
    Kanwar AJ. Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005;30:332–336.CrossRefPubMedGoogle Scholar
  9. 9.
    Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000;42:245–253.CrossRefPubMedGoogle Scholar
  10. 10.
    Njoo MD, Bossuyt PM, Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands. Int J Dermatolol 1999;38:866–872.CrossRefGoogle Scholar
  11. 11.
    Ongenae K, Van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004;14:177–181.PubMedGoogle Scholar
  12. 12.
    Cho S, Kang HC, Hahm J. Characteristics of vitiligo in Korean Children. Pediatr Dermatol 2000;17:189–193.CrossRefPubMedGoogle Scholar
  13. 13.
    Kwinter J, Pelletier J, Khambalia A, Pope E. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol 2007;56:236–241.CrossRefPubMedGoogle Scholar
  14. 14.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789–791.CrossRefPubMedGoogle Scholar
  15. 15.
    Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003;139:581–585.CrossRefPubMedGoogle Scholar
  16. 16.
    Silverberg N, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004;51:760–766.CrossRefPubMedGoogle Scholar
  17. 17.
    Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005;15:88–91.PubMedGoogle Scholar
  18. 18.
    Choi CW, Chang SE, Bak H, Choi JH, Park HS, Huh CH, et al. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol 2008;35:503–507.CrossRefPubMedGoogle Scholar
  19. 19.
    Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 1999;16:317–320.CrossRefPubMedGoogle Scholar
  20. 20.
    Leone G, Pacifico A, Iacovelli P, Paro Vidolin A, Picardo M. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006;31:200–205.CrossRefPubMedGoogle Scholar
  21. 21.
    Amano H, Abe M, Ishikawa O. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 2008;25:262–264.CrossRefPubMedGoogle Scholar
  22. 22.
    Travis L, Silverberg N. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004;21:495–498.CrossRefPubMedGoogle Scholar
  23. 23.
    Brazzelli V, Prestinari F, Castello M, Bellani E, Roveda E, Barbagallo T, et al. Useful treatment of vitiligo in 10 children with UV-B narrowband (311 nm). Pediatr Dermatol 2005;22:257–261.CrossRefPubMedGoogle Scholar
  24. 24.
    Kishan Kumar YH, Rao GR, Gopal KV, Shanti G, Rao KV. Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo. Indian J Dermatol Venereol Leprol 2009;75:162–166.CrossRefPubMedGoogle Scholar
  25. 25.
    Esposito M, Soda R, Costanzo A, Chimenti S. Treatment of vitiligo with the 308 nm excimer laser. Clin Exp Dermatol 2004;29:133–137.CrossRefPubMedGoogle Scholar
  26. 26.
    Hofer A, Hassan AS, Legat FJ, Kerl H, Wolf P. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol 2005;152:981–985.CrossRefPubMedGoogle Scholar
  27. 27.
    Xiang L. Once-weekly treatment of vitiligo with monochromatic excimer light 308 nm in Chinese patients. J Eur Acad Dermatol Venereol 2008;22:899–900.CrossRefPubMedGoogle Scholar
  28. 28.
    Atherton DJ, Cohen BL, Knobler E, Garzon M, Morelli JG, Tay YK, et al. Phototherapy for children. Pediatr Dermatol 1996;13:415–422.CrossRefPubMedGoogle Scholar
  29. 29.
    Caron-Schreinemachers AL, Kingswijk MM, Bos JD, Westerhof W. UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol 2005;85:24–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Schallreuter KU, Krüger C, Würfel BA, Panske A, Wood JM. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008;47:743–753.CrossRefPubMedGoogle Scholar
  31. 31.
    Silvan M. The psychological aspects of vitiligo. Cutis 2004;73:163–167.PubMedGoogle Scholar
  32. 32.
    Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 1999;135:407–413.CrossRefPubMedGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.First Pediatric Department Athens University, Aghia Sophia Children’s HospitalAthensGreece

Personalised recommendations